Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53

<table>BIBF1120 and paclitaxel increase the percentage of mitotic parental and paclitaxel-resistant Hec50co cells. Parental Hec50 (a) or paclitaxel-resistant Hec50A (b) or Hec50E (c) endometrial cancer cells were treated with 14 nM paclitaxel for 24 h with or without 1 <i>μ</i>M BIBF1120, followed by assessment of the percentage of mitotic cells.</table>

Obstetrics and Gynecology International

fig4

Figure 4

Figure 4: Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53 